The Latest Breaking News from Pfizer

WASHINGTON — Moderna Inc. plans to tell U.S. lawmakers that it more than adequately compensated the government for its role in a COVID-19 vaccine partnership that brought the drugmaker billions of dollars, a central point in what’s likely to be a heated Capitol Hill hearing this week.

Pfizer says its working to create new packaging for Nurtec ODT to comply with the child-resistant packaging requirements.

Pfizer’s COVID-19 pill Paxlovid won another vote of confidence from US health advisers Thursday, clearing the way for its full regulatory approval by the Food and Drug Administration. The medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021.

U.S. health advisersare backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness

Zero-commission trading platform Robinhood is highly attractive to Gen Z and millennial investors. Therefore, stocks traded on the Robinhood platform are considered popular and trending. While all Robinhood stocks are not fundamentally sound, Taiwan Semiconductor Manufacturing (TSM), Pfizer (PFE), General Motors (GM), and Nokia (NOK) hold the potential to deliver…

Pharma giant Pfizer (PFE) had a successful fiscal year 2022 with record-breaking revenue and earnings. Moreover, its recent acquisition should boost its portfolio and revenue. Given the market volatility, this fundamentally strong stock might be an ideal buy for under $50. Keep reading.

With inflation still alarmingly high, the Fed is poised to raise interest rates further. This is predicted to keep the stock market volatile. Amid this, investors should focus on their long-term strategies and buy fundamentally strong stocks Visa (V), Pfizer (PFE), and Molina Healthcare (MOH), which have solid growth potential.…

Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma.

Pfizer Inc. agreed to purchase cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, gaining the company’s antibody drugs that fight tumors.

WASHINGTON - US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.

Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.